From: Therapeutic efficacy of sorafenib and plant-derived phytochemicals in human colorectal cancer cells
Single and combined treatment with Sora and Que or Rsv | SW1116 | SW837 | ||||
---|---|---|---|---|---|---|
A. Single and combined treatment with Sora and Que. | IC-values (µM) | SR | P-value | IC-values (µM) | SR | P-value |
1. Sequential treatment with Sora and Que: Sora (24 h) followed by Que (48 h) | ||||||
 a. Sora (0.25- 10 µM) | IC60 = 0.57 | N.A | 0.337 vs. b 0.235 vs. c | IC50 = 6.86 | N.A | 0.395 vs. b 0.682 vs. c |
 b. Sora (0.25- 10 µM) + Que (60 µM) | IC60 = 1.14 | 0.500 | b | IC50 = 9.43 | 0.728 | b |
 c. Sora (0.25- 10 µM) + Que (120 µM) | IC60 = 2.00 | 0.300 | c | IC50 = 9.43 | 0.728 | c |
2. Inverted sequential treatment with Sora and Que: Que (24Â h) followed by Sora (48Â h) | ||||||
 a. Sora (0.25- 10 µM) | IC60 = 4.86 | N.A | - | IC50 = 6.86 | N.A | 0.006 vs. b 0.010 vs. c |
 b. Sora (0.25- 10 µM) + Que (60 µM) | IC60 = 3.43 | 1.420 | 0.353 | N.D | N.D | b |
 c. Sora (0.25- 10 µM) + Que (120 µM | IC60 = 2.00 | 2.430 | 0.152 | N.D | N.D | c |
3. simultaneous treatment with Sora and Que:(72Â h) | ||||||
 a. Sora (0.25- 10 µM) | IC80 = 4.00 | N.A | - | IC50 = 6.57 | N.A | 0.022 vs. b 0.189 vs. c |
 b. Sora (0.25- 10 µM) + Que (60 µM) | IC80 = 0.57 | 7.020 | 0.581 | N.D | N.D | b |
 c. Sora (0.25- 10 µM) + Que (120 µM | IC80 = 0.86 | 4.650 | 0.882 | 10.00 | 0.66 | c |
B. Single and combined treatment with Sora and Rsv | IC-values (µM) | SR | P-value | IC-values (µM) | SR | P-value |
1. Sequential treatment with Sora and Rsv: Sora (24Â h) followed by Rsv (48Â h) | ||||||
 a. Sora (0.25- 10 µM) | IC60 = 0.57 | N.A | 0.522 vs. b | IC50 = 6.86 | N.A | 0.452 vs. b 0.831 vs. c |
 b. Sora (0.25- 10 µM) + Rsv (40 µM) | IC60 = 1.14 | 0.500 | b | IC50 = 9.71 | 0.71 | b |
 c. Sora (0.25- 10 µM) + Rsv (80 µM) | IC60 = 1.70 | 0.340 | 0.883 | IC50 = 9.14 | 0.75 | c |
2. Inverted sequential treatment with Sora and Rsv: Rsv (24Â h) followed by Sora (48Â h) | ||||||
 a. Sora (0.25- 10 µM) | IC60 = 4.86 | N.A | - | IC50 = 6.57 | N.A | 0.003 vs. b 0.024 vs. c |
 b. Sora (0.25- 10 µM) + Rsv (40 µM) | IC60 = 0.86 | 5.650 | 0.001 | N.D | N.D | b |
 c. Sora (0.25- 10 µM) + Rsv (80 µM) | N.D | N.D | 0.0001 | N.D | N.D | c |
3. simultaneous treatment with Sora and Rsv: (72Â h) | ||||||
 a. Sora (0.25- 10 µM) | IC60 = 1.14 | N.A | - | IC60 = 7.71 | N.A | 0.044 vs. b 0.964 vs. c |
 b. Sora (0.25- 10 µM) + Rsv (40 µM) | IC60 = 0.57 | 2.00 | 0.238 | N.D | N.D | b |
 c. Sora (0.25- 10 µM) + Rsv (80 µM) | IC60 = 0.57 | 2.00 | 0.401 | IC60 = 6.57 | 1.170 | c |